Clinical Trial Update: A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache [Phase 3]

View source ↗

Summary

Phase 3 trial of galcanezumab (LY2951742) in episodic and chronic cluster headache completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cluster Headache

Drugs mentioned

• Galcanezumab (galcanezumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Episodic Cluster Headache, Chronic Cluster Headache | Phase 3 | Status: COMPLETED | Results posted: 2022-02-10